First Community Trust NA Sells 7,050 Shares of Zimmer Biomet Holdings, Inc. $ZBH

First Community Trust NA lowered its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 77.0% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 2,107 shares of the medical equipment provider’s stock after selling 7,050 shares during the period. First Community Trust NA’s holdings in Zimmer Biomet were worth $189,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of the company. Legacy Wealth Asset Management LLC raised its stake in shares of Zimmer Biomet by 2.3% in the 3rd quarter. Legacy Wealth Asset Management LLC now owns 4,670 shares of the medical equipment provider’s stock valued at $460,000 after buying an additional 106 shares in the last quarter. Global Retirement Partners LLC boosted its stake in Zimmer Biomet by 7.0% in the third quarter. Global Retirement Partners LLC now owns 1,686 shares of the medical equipment provider’s stock worth $166,000 after purchasing an additional 111 shares in the last quarter. Cullen Frost Bankers Inc. grew its holdings in Zimmer Biomet by 66.7% during the 3rd quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock worth $29,000 after acquiring an additional 116 shares during the last quarter. Generali Asset Management SPA SGR grew its stake in shares of Zimmer Biomet by 0.9% during the third quarter. Generali Asset Management SPA SGR now owns 14,232 shares of the medical equipment provider’s stock valued at $1,402,000 after purchasing an additional 122 shares during the last quarter. Finally, Brookstone Capital Management boosted its position in Zimmer Biomet by 1.3% in the 3rd quarter. Brookstone Capital Management now owns 9,350 shares of the medical equipment provider’s stock valued at $921,000 after buying an additional 123 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, SVP Lori Winkler sold 2,650 shares of the business’s stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $94.66, for a total value of $250,849.00. Following the completion of the sale, the senior vice president directly owned 10,224 shares in the company, valued at approximately $967,803.84. The trade was a 20.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 1.39% of the company’s stock.

Zimmer Biomet Price Performance

Shares of ZBH opened at $91.13 on Thursday. The company’s 50-day moving average is $92.18 and its 200-day moving average is $93.79. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.98 and a quick ratio of 1.10. The firm has a market capitalization of $17.83 billion, a PE ratio of 25.74, a PEG ratio of 1.85 and a beta of 0.61. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $84.59 and a fifty-two week high of $114.44.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.38 by $0.04. The company had revenue of $2.24 billion during the quarter, compared to analysts’ expectations of $2.22 billion. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The business’s revenue was up 10.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.31 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be paid a $0.24 dividend. The ex-dividend date is Tuesday, March 31st. This represents a $0.96 annualized dividend and a yield of 1.1%. Zimmer Biomet’s payout ratio is 27.12%.

Analyst Ratings Changes

ZBH has been the subject of several analyst reports. Barclays lowered their price target on shares of Zimmer Biomet from $104.00 to $100.00 and set an “underweight” rating for the company in a research report on Thursday, February 12th. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a report on Tuesday, February 10th. Wells Fargo & Company raised their price objective on shares of Zimmer Biomet from $93.00 to $98.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 11th. Evercore raised Zimmer Biomet from an “in-line” rating to an “outperform” rating and lifted their target price for the company from $94.00 to $120.00 in a research report on Monday, January 5th. Finally, TD Cowen upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Monday, January 26th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, ten have given a Hold rating and four have issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $106.20.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.